Jazz Pharmaceuticals (JAZZ) Business Metric Overview - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Jazz Pharmaceuticals

    NASDAQ: JAZZ · Real-Time Price · USD
    129.50
    1.48 (1.16%)
    At close: Sep 05, 2025, 3:59 PM
    129.50
    0.00%
    After-hours: Sep 05, 2025, 04:10 PM EDT

    Jazz Pharmaceuticals Revenue Breakdown

    Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015 Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014 Dec 31, 2013 Sep 30, 2013 Jun 30, 2013 Mar 31, 2013 Dec 31, 2012 Sep 30, 2012 Jun 30, 2012 Mar 31, 2012
    Defitelio-Defibrotide Revenue 48.11M 40.66M 57.65M 65.82M 45.42M 47.68M 47.73M 46.11M 39.08M 40.65M 49.45M 54.7M 49.49M 42.51M 57.7M 48.1M 49.62M 55.45M 50.24M 42.71M 47.43M 47.78M 37.6M 46.05M 41.5M 37.71M 36.18M 4M 6.03M 3.44M 6.07M 6.71M 6.35M 8.1M 251.75M 242.9M 247.85M 212.69M 222.5M 204.34M 191.37M 160.38M 164.18M 153.66M 133.74M 117.53M 113.51M 102.61M 89.1M 73.44M
    Defitelio-Defibrotide Revenue Growth +18.31% -29.47% -12.41% +44.91% -4.73% -0.11% +3.52% +17.99% -3.87% -17.79% -9.59% +10.52% +16.41% -26.33% +19.98% -3.07% -10.52% +10.38% +17.62% -9.95% -0.73% +27.06% -18.35% +10.98% +10.04% +4.24% +803.52% -33.58% +75.49% -43.37% -9.61% +5.73% -21.65% -96.78% +3.64% -2.00% +16.53% -4.41% +8.89% +6.78% +19.32% -2.32% +6.84% +14.90% +13.80% +3.53% +10.62% +15.17% +21.32% n/a
    Epidiolex-Epidyolex Revenue 251.73M 217.74M 275.05M 251.56M 247.1M 198.72M 213.71M 202.23M 188.91M 207M 196.22M 175.29M 157.89M 193.79M 160.38M 109.48M 2.78M 1.6M 1.87M 852K 2.52M 4.23M 4.48M 5.17M 3.67M 4.91M 3.81M 27.95M 26.23M 24.07M 9.72M 298.03M 272.33M 291.2M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Epidiolex-Epidyolex Revenue Growth +15.61% -20.84% +9.34% +1.80% +24.35% -7.02% +5.68% +7.05% -8.74% +5.49% +11.94% +11.02% -18.52% +20.83% +46.49% +3833.92% +74.37% -14.74% +119.72% -66.22% -40.34% -5.67% -13.36% +40.85% -25.20% +29.01% -86.39% +6.57% +8.96% +147.67% -96.74% +9.44% -6.48% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    High Sodium AG Oxybate Product Royalty Revenue Revenue 54.14M 48.95M 55.31M 58.16M 54.16M 49.95M 28.92M 5.51M 2.1M 3.07M 1M 1.63M 943K 1.03M 3.34M 2.64M 33.16M 30.99M 30.82M 26.57M 32.72M 31.52M 29.58M 31.36M 28.94M 25.62M 21.04M 356.01M 316.78M 312.48M 303.87M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    High Sodium AG Oxybate Product Royalty Revenue Revenue Growth +10.61% -11.50% -4.90% +7.37% +8.44% +72.70% +424.50% +163.07% -31.66% +206.39% -38.66% +73.06% -8.45% -69.20% +26.62% -92.03% +6.98% +0.54% +16.02% -18.80% +3.80% +6.56% -5.68% +8.36% +12.98% +21.77% -94.09% +12.38% +1.38% +2.83% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Other Products Revenue 4.41M 4.78M 2.97M 2.23M 2.7M 3.57M 2.91M 3.42M 3.43M 80.97M 73.51M 72.95M 54.22M 64.95M 20.67M 1.96M 335.55M 439.27M 447.81M 446.81M 407.88M 435.35M 425.64M 413.21M 368.32M 374.83M 357.25M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Other Products Revenue Growth -7.82% +60.79% +33.42% -17.38% -24.43% +22.81% -14.93% -0.50% -95.76% +10.15% +0.77% +34.55% -16.53% +214.19% +954.26% -99.42% -23.61% -1.91% +0.22% +9.55% -6.31% +2.28% +3.01% +12.19% -1.74% +4.92% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Other Royalty And Contract Revenues Revenue 6M 9.48M 101.49M 7.11M 5.52M 9.93M 4.82M 4.82M 6.5M 4.72M 3.22M 4.14M 4.74M 4.65M 6.1M 31.45M 75.42M 53.44M 36.94M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Other Royalty And Contract Revenues Revenue Growth -36.66% -90.66% +1328.39% +28.78% -44.46% +106.06% +0.10% -25.87% +37.62% +46.61% -22.26% -12.65% +2.00% -23.75% -80.62% -58.29% +41.13% +44.66% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Rylaze-Enrylaze Revenue 100.66M 94.23M 5.17M 98.78M 107.83M 102.75M 104.86M 101.69M 85.93M 30.27M 30.07M 33.89M 33.76M 34.76M 34.69M 334.18M 54.33M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Rylaze-Enrylaze Revenue Growth +6.82% +1721.63% -94.76% -8.39% +4.94% -2.01% +3.11% +18.35% +183.91% +0.66% -11.28% +0.39% -2.90% +0.22% -89.62% +515.05% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Sativex Revenue 4.62M 5.41M 53.25M 4.59M 6.38M 2.73M 4.63M 2.81M 7.1M 247.5M 256.04M 269.42M 247.5M 288.76M 307.33M 124.16M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Sativex Revenue Growth -14.65% -89.85% +1061.08% -28.15% +133.38% -40.89% +64.90% -60.47% -97.13% -3.34% -4.97% +8.86% -14.29% -6.04% +147.52% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Vyxeos Revenue 44.85M 29.54M 49.29M 34.31M 43.01M 32.02M 29.83M 34.06M 36.7M 281.38M 255.94M 235.03M 186.08M 182.65M 153.06M 55.92M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Vyxeos Revenue Growth +51.81% -40.06% +43.65% -20.22% +34.32% +7.36% -12.42% -7.20% -86.96% +9.94% +8.90% +26.30% +1.88% +19.33% +173.70% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Xyrem Revenue 35.35M 37.24M 400.96M 58.11M 62.18M 64.23M 125.11M 159.77M 178.13M 71.97M 70.32M 68.28M 59.34M 64.84M 71.71M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Xyrem Revenue Growth -5.08% -90.71% +589.96% -6.54% -3.19% -48.66% -21.69% -10.31% +147.51% +2.34% +2.98% +15.08% -8.48% -9.59% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Xywav Revenue 415.32M 344.8M 78.33M 388.47M 368.47M 315.3M 331.63M 326.56M 277.76M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Xywav Revenue Growth +20.45% +340.21% -79.84% +5.43% +16.86% -4.93% +1.55% +17.57% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Zepzelca Revenue 74.54M 63.03M n/a 85.84M 81.05M 75.1M 77.99M 70.35M 67.18M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Zepzelca Revenue Growth +18.26% n/a n/a +5.92% +7.92% -3.71% +10.87% +4.71% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Ziihera Revenue 5.99M 1.98M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Ziihera Revenue Growth +203.34% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a

    Revenue by Geography

    Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015 Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014 Dec 31, 2013 Sep 30, 2013 Jun 30, 2013 Mar 31, 2013 Dec 31, 2012 Sep 30, 2012 Jun 30, 2012 Mar 31, 2012
    Europe Revenue 82.76M 83.61M 81.87M 77.32M 82.16M 71.36M 68.97M 59.33M 65.9M 57.81M 60.02M 60.78M 61.03M 64.92M 70.73M 47.27M 47.23M 49.98M 45.78M 37.9M 41.56M 43.24M 35.04M 36.52M 35.4M 31.75M 30.82M 35.02M 28.33M 39.12M 24.94M 27.38M 31.35M 26.59M 25.79M 28.75M 25.02M 20.78M 26.08M 24.13M 32.63M 39.11M 32.58M 30.69M 24.34M 15.07M 19.33M 13.07M 14.36M 17.34M 12.16M 3.17M 5.91M
    Europe Revenue Growth -1.01% +2.12% +5.89% -5.89% +15.14% +3.46% +16.25% -9.97% +14.00% -3.69% -1.24% -0.41% -6.00% -8.21% +49.63% +0.08% -5.49% +9.18% +20.80% -8.81% -3.91% +23.43% -4.06% +3.16% +11.51% +3.02% -12.00% +23.60% -27.58% +56.88% -8.92% -12.68% +17.91% +3.11% -10.30% +14.90% +20.42% -20.32% +8.09% -26.08% -16.55% +20.04% +6.16% +26.06% +61.48% -22.02% +47.87% -8.97% -17.17% +42.55% +283.48% -46.36% n/a
    Other Countries Revenue 26.67M 16.29M 32.66M 23.98M 17.07M 22.41M 18.59M 13.28M 16.8M 10.7M 12.79M 13.76M 12.11M 7.98M 10.16M 13.64M 12.06M 13.99M 6.7M 8.44M 14.69M 9.34M 10.3M 16.68M 9.92M 7.91M 8.83M 10.1M 10.6M 2.54M 14.07M 10.32M 5.52M 6.67M 8.57M 6.56M 5.11M 315.48M 305.58M 302.56M 269.25M 280.2M 264.72M 247.53M 214.96M 215.03M 209.3M 191.27M 176.91M n/a 159.95M n/a n/a
    Other Countries Revenue Growth +63.71% -50.13% +36.21% +40.46% -23.82% +20.57% +39.95% -20.92% +57.05% -16.40% -7.02% +13.62% +51.70% -21.41% -25.53% +13.15% -13.81% +108.76% -20.65% -42.51% +57.30% -9.34% -38.27% +68.12% +25.45% -10.40% -12.61% -4.65% +317.78% -81.98% +36.34% +87.04% -17.25% -22.18% +30.63% +28.33% -98.38% +3.24% +1.00% +12.37% -3.91% +5.85% +6.95% +15.15% -0.04% +2.74% +9.42% +8.12% n/a n/a n/a n/a n/a
    United States Revenue 936.28M 797.95M 973.63M 953.67M 924.59M 808.21M 884.58M 884.71M 810.12M 903.62M 867.84M 858.34M 740.58M 823.82M 757.23M 690.9M 548.29M 601.55M 548.41M 516.1M 478.48M 529.16M 492.37M 480.93M 462.86M 436.8M 429.73M 455.36M 405.69M 394.74M 372.85M 356.69M 339.18M 363.36M 339.82M 345.85M 305.88M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    United States Revenue Growth +17.34% -18.04% +2.09% +3.14% +14.40% -8.63% -0.01% +9.21% -10.35% +4.12% +1.11% +15.90% -10.10% +8.79% +9.60% +26.01% -8.85% +9.69% +6.26% +7.86% -9.58% +7.47% +2.38% +3.90% +5.97% +1.65% -5.63% +12.24% +2.77% +5.87% +4.53% +5.16% -6.65% +6.93% -1.74% +13.07% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a

    Operating Expense Breakdown

    Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
    Selling, General, and Administrative Revenue 358.4M 514.01M 369.29M 325.77M 338.52M 351.71M 396.03M 308.31M 340.84M 297.92M 383.2M 358.48M 366.47M 308.81M 398.46M 363.68M 429.03M 260.51M 247.17M 207.25M 191.41M 208.4M 214.28M 178.71M 176.01M 167.95M 161.87M 155.87M 158.58M 207.21M 143.05M 124.52M 132.33M 144.25M 127.14M 124.37M 122.62M 128.76M 125.56M 104.04M 107.13M 112.39M
    Selling, General, and Administrative Revenue Growth -30.27% +39.19% +13.36% -3.77% -3.75% -11.19% +28.45% -9.55% +14.41% -22.26% +6.90% -2.18% +18.67% -22.50% +9.56% -15.23% +64.69% +5.40% +19.26% +8.28% -8.15% -2.74% +19.90% +1.53% +4.80% +3.76% +3.84% -1.71% -23.47% +44.85% +14.88% -5.90% -8.27% +13.46% +2.23% +1.43% -4.77% +2.56% +20.67% -2.88% -4.68% n/a
    Research and Development Revenue 189.97M 180.65M 240.5M 199.92M 220.73M 222.85M 216.61M 234.4M 209.24M 189.41M 172.56M 148.87M 139.05M 129.98M 155.44M 141.04M 132.7M 76.57M 91.7M 78.65M 78.92M 86.11M 97.38M 79.86M 62.38M 60.1M 56.66M 51.16M 56.13M 62.67M 66M 47.36M 40.16M 44.93M 44.16M 47.8M 39.09M 31.25M 29.45M 50.78M 27.83M 27.18M
    Research and Development Revenue Growth +5.16% -24.88% +20.30% -9.43% -0.95% +2.88% -7.59% +12.03% +10.47% +9.77% +15.91% +7.06% +6.97% -16.38% +10.22% +6.29% +73.29% -16.50% +16.60% -0.35% -8.34% -11.58% +21.95% +28.01% +3.79% +6.09% +10.74% -8.86% -10.43% -5.04% +39.34% +17.94% -10.62% +1.74% -7.61% +22.27% +25.08% +6.10% -42.00% +82.46% +2.40% n/a

    Add to Watchlist